Clopidogrel BGR

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0040	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	24/02/2020		SmPC and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IA/0039	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	22/11/2019	n/a		
IAIN/0038/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	23/10/2019	n/a		
IB/0037/G	This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	25/09/2019	24/10/2019	SmPC, Annex II, Labelling and PL	

	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0036	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	05/06/2019	24/10/2019	SmPC, Labelling and PL	
IB/0035	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	26/04/2019	24/10/2019	SmPC	
IB/0034	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	26/04/2018	02/04/2019	SmPC and PL	
IA/0033/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	20/03/2018	n/a		

	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IA/0032	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	18/01/2018	n/a		
IB/0031/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	22/06/2017	19/07/2017	SmPC, Labelling and PL	
IA/0030	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	09/06/2017	n/a		

IB/0029/G	This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms	08/06/2016	22/05/2017	SmPC, Labelling and PL	
IB/0028/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	08/12/2015	02/06/2016	SmPC, Annex II and PL	

IAIN/0027	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	30/09/2015	02/06/2016	Annex II and PL	
IAIN/0026	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	30/09/2015	n/a		
IB/0025	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	12/06/2015	02/06/2016	SmPC and PL	
IAIN/0024/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	02/12/2014	n/a		
IAIN/0023	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	27/10/2014	n/a		

IB/0022	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	07/10/2014	n/a		
IAIN/0021	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	15/09/2014	n/a		
T/0020	Transfer of marketing authorisation from Krka, d.d., Novo mesto to Laboratoires BIOGARAN, France. Transfer of Marketing Authorisation	15/07/2014	27/08/2014	SmPC, Labelling and PL	Transfer of marketing authorisation from Krka, d.d., Novo mesto to Laboratoires BIOGARAN, France.
IB/0018	B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	25/07/2014	n/a		
IAIN/0019	A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs	14/07/2014	27/08/2014	SmPC, Labelling and PL	
PSUSA/820/201311	Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel	10/07/2014	n/a		PRAC Recommendation - maintenance
IAIN/0017/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters	23/05/2014	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS				
R/0013	Renewal of the marketing authorisation.	20/03/2014	08/05/2014	SmPC and PL	The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. No literature review on the efficacy/effectiveness has been submitted by the MAH within this application. Since the clinical efficacy of clopidogrel in the approved indications is well established and evidence of clinical efficacy has been discussed at time of approval the CHMP finds acceptable the MAH approach of not performing a literature review on the efficacy/effectiveness of clopidogrel. The beneficial effect of Zylagren remains in line with that of the originator product (Plavix), and is considered positive. The CHMP therefore recommended that the Marketing Authorisation for Zylagren can be renewed with unlimited validity.
IB/0016/G	This was an application for a group of variations. To update sections 4.4 and 4.5 of the SmPC to add information on an interaction with the selective serotonin reuptake inhibitors (SSRIs) in section 4.5 and consequential information concerning this interaction in section 4.4. The Package leaflet has been updated accordingly.	23/04/2014	27/08/2014	SmPC and PL	

	To update 4.8 of the SmPC to add "Rash exfoliative" as a new undesirable effect. Furthermore minor editorial correction to DE, HR, NO and PL text were introduced. These changes have been previously approved for the reference medicinal product Plavix in WS/476 and WS/477 respectively. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0012/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	24/02/2014	n/a		

IB/0014	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	19/02/2014	08/05/2014	SmPC	
IAIN/0011	B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing	13/12/2013	08/05/2014	Annex II and PL	
IA/0010	B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	09/12/2013	n/a		
IB/0009/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	21/10/2013	08/05/2014	SmPC	
IB/0008/G	This was an application for a group of variations.	05/08/2013	08/05/2014	SmPC, Annex II, Labelling	

	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH			and PL	
IA/0007/G	This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size	17/12/2012	n/a		
IB/0006/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size A.7 - Administrative change - Deletion of	21/11/2012	n/a		

	manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation				
IB/0005/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	29/08/2011	n/a	SmPC	
IB/0004	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	15/04/2011	n/a	SmPC, Annex II and PL	To update SPC sections 4.2 "Posology and method of administration", 4.4 "Special warnings and precautions for use", 4.5 "Interaction with other medicinal products and other forms of interaction" and 5.2 "Pharmacokinetic properties" of clopidogrel/acetyisalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study.

					Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3). Additionally Annex II was updated with regards to Pharmacovigilance system. We also made minor correction in List of local representatives for Estonia, Lativa, Poland, Austria, Greece, Lithuania, Cyprus and United Kingdom.
IA/0003	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size	20/12/2010	n/a		
IB/0002	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	22/07/2010	n/a	SmPC and PL	
IB/0001	IB_42_a_01_Change in shelf-life of finished product - as packaged for sale	17/11/2009	n/a	SmPC	